Literature DB >> 7894884

Psychiatric illness in patients with persistent somatisation.

P Fink1.   

Abstract

BACKGROUND: This study explores the incidence and nature of mental illness among persistent somatisers, and analyses their use of mental health services.
METHOD: Individuals with at least ten admissions to non-psychiatric departments during an 8-year period were studied. Persistent somatisers (n = 56) were compared with other frequent users (n = 57) of non-psychiatric services.
RESULTS: Of the persistent somatisers, 82% had been examined by a psychiatrist at least once (median, 3 times). Sixteen per cent were mentally retarded, 48% were dependent on alcohol or drugs, and 48% had DSM-III-R personality disorder. The most prevalent ICD-10 diagnoses were anxiety states (54%), depressions (30%), phobias (18%) and psychoses (20%).
CONCLUSIONS: Persistent somatisation is associated with severe mental illness and a broad spectrum of heterogeneous psychiatric diagnoses and syndromes. Persistent somatisers impose a serious burden on the mental health care system.

Entities:  

Mesh:

Year:  1995        PMID: 7894884     DOI: 10.1192/bjp.166.1.93

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  3 in total

1.  Psychotropic drug use in Israel: results from the national health survey.

Authors:  Alexander Grinshpoon; Eli Marom; Abraham Weizman; Alexander M Ponizovsky
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  [The Explanatory Model-Interview in the diagnosis of orthopaedic pain patients].

Authors:  C Schröter; M Schiltenwolf; T Fydrich; P Henningsen
Journal:  Orthopade       Date:  2004-05       Impact factor: 1.087

3.  [Pain and consciousness. Articles from the summer workshop held by the German Interdisciplinary Collaboration for Pain Therapy (DIVS) in 2005].

Authors:  H Laubenthal; M Valet; T Sprenger; A Wöller; T R Tölle; H Röpcke; S Wirz; C Schröter; M Schiltenwolf; P Henningsen; T Sundermeier; H J Ebell; N Kohnen; W Häuser
Journal:  Schmerz       Date:  2007-06       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.